Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Expanding the repertoire reveals recurrent, cryptic, and hematopoietic HLA class I minor histocompatibility antigens.
Fuchs KJ, van de Meent M, Honders MW, Khatri I, Kester MGD, Koster EAS, Koutsoumpli G, de Ru AH, van Bergen CAM, van Veelen PA, 't Hoen PAC, van Balen P, van den Akker EB, Veelken JH, Halkes CJM, Falkenburg JHF, Griffioen M. Fuchs KJ, et al. Among authors: van de meent m. Blood. 2024 May 2;143(18):1856-1872. doi: 10.1182/blood.2023022343. Blood. 2024. PMID: 38427583 Free PMC article.
Successful generation of primary virus-specific and anti-tumor T-cell responses from the naive donor T-cell repertoire is determined by the balance between antigen-specific precursor T cells and regulatory T cells.
Jedema I, van de Meent M, Pots J, Kester MG, van der Beek MT, Falkenburg JH. Jedema I, et al. Among authors: van der beek mt, van de meent m. Haematologica. 2011 Aug;96(8):1204-12. doi: 10.3324/haematol.2010.039099. Epub 2011 May 5. Haematologica. 2011. PMID: 21546501 Free PMC article.
Allogeneic HLA-A*02-restricted WT1-specific T cells from mismatched donors are highly reactive but show off-target promiscuity.
Falkenburg WJ, Melenhorst JJ, van de Meent M, Kester MG, Hombrink P, Heemskerk MH, Hagedoorn RS, Gostick E, Price DA, Falkenburg JH, Barrett AJ, Jedema I. Falkenburg WJ, et al. Among authors: van de meent m. J Immunol. 2011 Sep 1;187(5):2824-33. doi: 10.4049/jimmunol.1100852. Epub 2011 Aug 5. J Immunol. 2011. PMID: 21821799 Free article.
Effective treatment of refractory CMV reactivation after allogeneic stem cell transplantation with in vitro-generated CMV pp65-specific CD8+ T-cell lines.
Meij P, Jedema I, Zandvliet ML, van der Heiden PL, van de Meent M, van Egmond HM, van Liempt E, Hoogstraten C, Kruithof S, Veld S, Marijt EW, von dem Borne PA, Lankester AC, Halkes CJ, Falkenburg JH. Meij P, et al. Among authors: van egmond hm, van der heiden pl, van liempt e, van de meent m. J Immunother. 2012 Oct;35(8):621-8. doi: 10.1097/CJI.0b013e31826e35f6. J Immunother. 2012. PMID: 22996368 Clinical Trial.
HLA class II upregulation during viral infection leads to HLA-DP-directed graft-versus-host disease after CD4+ donor lymphocyte infusion.
Stevanovic S, van Bergen CA, van Luxemburg-Heijs SA, van der Zouwen B, Jordanova ES, Kruisselbrink AB, van de Meent M, Harskamp JC, Claas FH, Marijt EW, Zwaginga JJ, Halkes CJ, Jedema I, Griffioen M, Falkenburg JH. Stevanovic S, et al. Among authors: van luxemburg heijs sa, van der zouwen b, van de meent m, van bergen ca. Blood. 2013 Sep 12;122(11):1963-73. doi: 10.1182/blood-2012-12-470872. Epub 2013 Jun 18. Blood. 2013. PMID: 23777765 Free article. Clinical Trial.
High Mutation Frequency of the PIGA Gene in T Cells Results in Reconstitution of GPI Anchor-/CD52- T Cells That Can Give Early Immune Protection after Alemtuzumab-Based T Cell-Depleted Allogeneic Stem Cell Transplantation.
Loeff FC, Falkenburg JHF, Hageman L, Huisman W, Veld SAJ, van Egmond HME, van de Meent M, von dem Borne PA, Veelken H, Halkes CJM, Jedema I. Loeff FC, et al. Among authors: van de meent m, van egmond hme. J Immunol. 2018 Mar 15;200(6):2199-2208. doi: 10.4049/jimmunol.1701018. Epub 2018 Feb 2. J Immunol. 2018. PMID: 29427418
CMV seronegative donors: Effect on clinical severity of CMV infection and reconstitution of CMV-specific immunity.
van der Heiden PLJ, van Egmond HM, Veld SAJ, van de Meent M, Eefting M, de Wreede LC, Halkes CJM, Falkenburg JHF, Marijt WAF, Jedema I. van der Heiden PLJ, et al. Among authors: van egmond hm, van de meent m, de wreede lc. Transpl Immunol. 2018 Aug;49:54-58. doi: 10.1016/j.trim.2018.04.003. Epub 2018 Apr 18. Transpl Immunol. 2018. PMID: 29679650
37 results